Adaptive Biotechnologies Corp — Director's Dealing 2019

Jun 27, 2019

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Adaptive Biotechnologies Corp (ADPT)
CIK: 0001478320
Period of Report: 2019-06-26

Reporting Person: ROBINS CHAD M (Director, CEO and Chairman)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	1787500	Direct
Common Stock	2237500	Indirect
Common Stock	500000	Indirect
Common Stock	350000	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$0.33	2021-12-20	Common Stock (800000)		Direct
Stock Option (Right to Buy)	$6.32	2025-06-09	Common Stock (800000)		Direct
Stock Option (Right to Buy)	$6.55	2028-02-07	Common Stock (600000)		Direct
Stock Option (Right to Buy)	$7.27	2029-02-07	Common Stock (410000)		Direct
Series E-1 Preferred Stock	$0.0		Common Stock (70680)		Direct

Footnotes

F1: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

F2: The option is fully vested and exercisable.

F3: The options vested with respect to 1/4 of such shares on November 1, 2018, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

F4: The options vest with respect to 1/4 of such shares on January 1, 2020, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

F5: The shares of preferred stock will convert immediately upon the closing of an initial public offering of the Issuer's common stock on a one-for-one basis and have no expiration date.